Halozyme Therapeutics, Inc.

HALO · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Assets
Cash & Equivalents$420$62$176$116
Short-Term Investments$282$486$572$480
Receivables$346$316$305$308
Inventory$186$182$165$142
Other Curr. Assets$95$77$45$39
Total Curr. Assets$1,329$1,123$1,262$1,085
Property Plant & Equip (Net)$71$72$73$75
Goodwill$417$417$417$417
Intangibles$349$366$384$402
Long-Term Investments$0$0$0$0
Tax Assets$0$20$5$4
Other NC Assets$56$56$56$81
Total NC Assets$892$931$935$978
Other Assets$0$0$0$0
Total Assets$2,221$2,054$2,197$2,063
Liabilities
Payables$15$19$20$10
Short-Term Debt$711$0$0$0
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$111$0$0$0
Total Curr. Liab.$837$134$150$139
LT Debt$800$1,509$1,507$1,506
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$8$0$0$0
Other NC Liab.$72$78$56$55
Total NC Liab.$880$1,587$1,564$1,561
Other Liabilities$0$0$0$0
Cap. Leases$0$0$0$0
Total Liabilities$1,717$1,721$1,714$1,700
Equity
Pref Stock$0$0$0$0
Common Stock$0$0$0$0
Retained Earnings$502$361$478$360
AOCI-$22-$28-$3$4
Other Equity$0$0$0$0
Total Equity$504$333$482$364
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$2,221$2,054$2,197$2,063
Net Debt$1,091$1,447$1,331$1,390